I-SPY 2 data presented recently at the San Antonio Breast Cancer Symposium shows that when added to standard, pre-surgery chemotherapy, the molecularly targeted experimental drug veliparib (
The I-SPY 2 trial uses a unique adaptive design to match experimental therapies with patients. Genetic or biological markers ("biomarkers") from individual patients' tumors are used to screen promising new treatments, identifying which treatments are most effective in specific types of patients. The adaptive trial design enables researchers to use early data from one set of patients to guide decisions about which treatments might be more useful for patients later in the trial, while minimizing the exposure of patients to treatments that do not benefit them.
Eligible patients enrolled in the trial are randomly assigned to standard neoadjuvant chemotherapy, including paclitaxel, followed by anthracycline-based chemotherapy, or they receive paclitaxel in combination with a novel agent followed by anthracycline-based chemotherapy before surgery. Each woman has a four-to-one chance of being randomized to receive an experimental agent.
"The I-SPY 2 trial is among our most ambitious partnership projects," said Dr.
The trial's adaptive statistical design was developed by the overall principal investigators for the I-SPY trial,
"What's so exciting about these two I-SPY 2 graduations--especially looking at challenges of triple-negative and HER2 medicine--is that we are making significant inroads into not only understanding the cancers, but providing women with promising new options to standard treatment, much more quickly, that could dramatically change their odds of survival," said Dr. Esserman.
The I-SPY 2 trial has the ability to stop assigning a therapy to subtypes of patients for whom it is offering no benefit, while at the same time, increasing its use to other subtypes where it is performing very well," said Dr. Berry. "This has actually happened in the trial. The design is great for patients in the trial, while at the same time accelerating drug development and making it more accurate. A principal goal is to enable small, focused phase III trials in early breast cancer, where therapies are more effective."
The large-scale trial involves a unique collaboration of scientists from the
I-SPY 2 has the potential to significantly reduce the cost of drug development and speed the process of screening drugs with the goal of bringing safe and effective new drugs to market more efficiently. I-SPY 2 was designed to address the problem that historically it has taken over
A distinctive feature of the trial is that it screens multiple drugs from multiple companies--up to 12 different cancer drugs over the course of the trial. This allows the I-SPY 2 team to graduate, drop and add drugs seamlessly throughout the course of the trial without having to stop the trial to write a whole new protocol, a process that dramatically reduces the time it takes to move from one drug to another in the trial.
"The I-SPY 2 standing trial is a direct path to personalized medicine," said Dr. Esserman. "The approach that we've developed through QuantumLeap Healthcare Collaborative means that everyone can learn faster together, allowing us to dramatically reduce the amount of time and cost involved with bringing drugs to market. This isn't just a matter of more efficient R&D, it is critical for women with fast-acting cancers whose lives are on the line until we find tolerable treatments targeted to their specific genetics and disease."
I-SPY 2, which is now sponsored by QuantumLeap, was launched in 2010 through the
Results from the trial will be published by the investigators via articles in peer-reviewed scientific journals. The large amount of valuable biomarker and clinical data to be generated by the project will be stored in a database at
Keywords for this news article include: Therapy, Treatment, Gonadal Hormones, Progesterone Congeners, Government Agencies Offices and Entities,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Top Hispanic Tech Companies Push for the Top
- 5 Notable Hispanic Technology Executives
- Russia, Crimea Discuss Referendum
- 'Holy grail of guitars' OM-45 Deluxe Available in in NY Auction
- California Establishes Center for Coffee Study
- Justin Bieber Loses Cool Over Selena Gomez
- Taco Bell Rings Up Breakfast Menu
- Maya Angelou Cancels Milagro Gala Appearance Due to Illness
- China Urges Malaysia Flight Emergency Response
- Spotify Picking up Echo Nest